Instil Bio (TIL)
(Delayed Data from NSDQ)
$11.04 USD
+0.44 (4.15%)
Updated May 30, 2024 04:00 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Instil Bio, Inc. [TIL]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on ITIL-306 Phase 1 Data in 2024; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
First TIL Approval Validates Cell Therapy Class
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on ITIL-306 Data in 2024; Strategic Updates; Adjusting PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
ITIL-306 Phase 1 NSCLC Data in 2024; 3Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Initiating for ITIL-306 in 2H23; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
InsTILing Novel Engineering Into Cell Therapy; Initiating at Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Instil Bio, Inc.
Industry: Medical - Biomedical and Genetics
|